Applications: Blood-Based Neuronal Blood Biomarkers by Disease Area
Neuronal blood biomarkers are emerging as a revolutionary tool in the realm of neurodegenerative disease research and diagnosis. They offer a non-invasive alternative to traditional methods, such as cerebrospinal fluid (CSF) sampling, thereby enhancing patient comfort and compliance in clinical settings. In this article, we will explore the applications of neuronal blood biomarkers across various disease areas, highlighting their significance, methodology, and the impact they have on patient outcomes.
NeuroDex isolates neuron-derived extracellular vesicles (NDEs) from a routine blood draw with its ExoSORT™ platform, a state-of-the-art technology that preserves the integrity of biomarkers. This method involves the extraction and analysis of disease proteins within these vesicles, transforming proteins such as TDP-43 and α-synuclein—often associated with neurodegenerative disorders—into neuron-specific blood biomarkers. Drug developers leverage these biomarkers for a variety of purposes including target engagement, pharmacodynamics assessments, strategic patient selection, and longitudinal monitoring of disease progression, all without the need for invasive lumbar punctures. By utilizing neuronal blood biomarkers, researchers can detect subtle changes in neuronal health and function, potentially leading to earlier intervention and improved therapeutic strategies.
These neuronal blood biomarkers play an essential role in understanding various neurodegenerative conditions, such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). Their ability to reflect the underlying pathophysiological changes provides clinicians with valuable insights into disease mechanisms, progression, and the effectiveness of therapeutic interventions. For instance, the correlation between specific biomarkers and clinical outcomes can guide personalized treatment approaches, ultimately leading to better patient management.
| Disease area | Lead NDE biomarkers | Key evidence |
|---|---|---|
| Alzheimer’s disease | Tau/pTau, synaptic panel (NRGN, GAP43, PSD95, Syntaxin-1, GluR2, proBDNF), AKT/insulin signaling | Studies indicate that synaptic markers can differentiate early Alzheimer’s disease from control groups, providing evidence of neurodegeneration. Recent research published in JCEM 2026 demonstrates central GLP-1 and PPARγ target engagement from plasma analysis, showcasing the potential of these biomarkers in clinical settings. |
| Parkinson’s disease, LBD and MSA | α-synuclein, LC3 and Cathepsin D, synaptic proteins | Research findings show over 80% sensitivity and specificity for CSF α-synuclein seeding positivity in a cohort of 150 patients, validated by the MJFF-funded PPMI study, highlighting the reliability of these biomarkers in diagnosing Parkinson’s disease. |
| ALS and FTD | TDP-43, with NfL and pathway markers | In multiple studies, TDP-43 biomarkers successfully separated sporadic ALS from control groups across three cohorts, while a significant treatment effect was noted in the Phase 2b PARADIGM trial, reinforcing the importance of these biomarkers in monitoring disease effects and guiding therapeutic decisions. |
Commonalities Across Disease Areas
Understanding Neuronal Blood Biomarkers
Regardless of the specific neurodegenerative conditions being studied, several commonalities exist in the methodologies employed for the analysis of neuronal blood biomarkers. These shared characteristics ensure the reliability and validity of findings across different disease areas:
- Sample: EDTA plasma (serum also accepted), minimum 500 µL per sample, shipped frozen on dry ice to maintain sample integrity during transit.
- Quality: Testing is conducted in a CLIA-certified clinical testing laboratory and GCLP-aligned clinical trial laboratory, ensuring adherence to stringent quality standards. The workflows are SOP-driven and performed on GLP-compliant instruments to guarantee accuracy and precision.
- Trial phases: Our services encompass a wide range of stages, from preclinical research through to Phase 2b clinical trials, allowing for comprehensive biomarker evaluation.
- Turnaround: The turnaround time for results is typically 2–3 weeks from sample receipt to report generation, depending on the size and complexity of the study.
- Sample: EDTA plasma (serum also accepted), minimum 500 µL per sample, shipped frozen on dry ice
- Quality: CLIA-certified clinical testing laboratory and GCLP-aligned clinical trial laboratory, SOP-driven workflows on GLP-compliant instruments
- Trial phases: preclinical through Phase 2b clinical trials
- Turnaround: 2–3 weeks from sample receipt to report, depending on study size
For further exploration of neuronal blood biomarkers, we invite you to review our publications that detail the latest research findings, our comprehensive biomarker pipeline showcasing ongoing projects, and our extensive research services tailored for clinical and preclinical studies. Should you have any inquiries or wish to collaborate on a study, please contact our team. Our experts are dedicated to advancing the field of neurodegenerative disease research through innovative use of neuronal blood biomarkers.
Furthermore, the utilization of neuronal blood biomarkers has significantly altered the landscape of clinical trials. By enabling quicker and more reliable assessments of drug efficacy, these biomarkers have the potential to accelerate the drug development process. The ability to monitor patients longitudinally allows researchers to evaluate treatment responses in real-time, leading to more informed decisions about drug dosing and adjustments in therapy. Additionally, the incorporation of these biomarkers into routine clinical practice could facilitate early intervention strategies, ultimately improving patient outcomes and enhancing the quality of life for those affected by neurodegenerative diseases.